DGAP-News Abivax announces webcast and teleconference following recent oversubscribed capital increase of EUR 28m at market price
DGAP-News: ABIVAX / Key word(s): Miscellaneous
Abivax announces webcast and teleconference following recent oversubscribed capital increase of EUR 28m at market price
PARIS, November 02, 2020 - 2:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces that its senior management will host a webcast and teleconference on Tuesday, November 3, 2020 at 3:00 pm CET (Paris time), to discuss the recently announced oversubscribed capital increase of EUR 28m at market price, company developments as well as address questions.
Attendees can participate by weblink (https://channel.royalcast.com/webcast/abivaxwebcast/20201103_1/) or connect by phone using the following telephone numbers.
Dial in details for participants:
France: +33 (0) 1 7037 7166
UK (Standard International Access): +44 (0) 20 3003 2666
U.S.: +1 212 999 6659
Belgium: +32 (0) 2 789 8603
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is
listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory
diseases, and ABX196 to treat hepatocellular carcinoma.
More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
+33 6 24 50 69 63
+41 79 367 6254
Press Relations & Investors Europe
MC Services AG
+49 211 529 252 22
Public Relations France
+33 6 21 10 49 24
Public Relations France
Thomas Roborel de Climens
+33 6 14 50 15 84
Public Relations USA
Rooney Partners LLC
+1 212 223 4017
02.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
1144669 02.11.2020Abivax Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de